<DOC>
	<DOC>NCT02598570</DOC>
	<brief_summary>This study seeks to evaluate the safety and pharmacokinetics of duvelisib in Japanese participants with relapsed or refractory lymphoma.</brief_summary>
	<brief_title>Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Diagnosis of lymphoma (excluding lymphoblastic lymphoma) Progressed during, refractory to, intolerant of, or ineligible for established therapy, or has a disease for which there is no established therapy Eastern Cooperative Oncology Group (ECOG) performance status lower than or equal to 2 Life expectancy of at least 3 months Any prior treatment with a PI3K inhibitor or Bruton's tyrosine kinase (BTK) inhibitor Ongoing treatment with chronic immunesuppressants Overt CNS lymphoma Inadequate hepatic, bone marrow, or renal function History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months Venous thromboembolic event requiring anticoagulation Presence of active systemic infection within 72 hours of treatment Human immunodeficiency virus (HIV) infection Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Relapsed Lymphoma</keyword>
	<keyword>Phosphoinositide 3-kinase (PI3K) Inhibitor</keyword>
	<keyword>Duvelisib</keyword>
	<keyword>Japanese</keyword>
	<keyword>Refractory Lymphoma</keyword>
</DOC>